Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer Journal Article


Authors: Thompson, R. H.; Allison, J. P.; Kwon, E. D.
Article Title: Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
Abstract: Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer. © 2006 Elsevier Inc. All rights reserved.
Keywords: unclassified drug; clinical trial; drug tolerability; review; hepatitis; nonhuman; rituximab; phenotype; animals; ipilimumab; cancer immunotherapy; melanoma; steroid; drug potency; transgenic mouse; monoclonal antibody; prostate cancer; prostatic neoplasms; b cell lymphoma; t lymphocyte receptor; antibodies, monoclonal; immunotherapy; genetic engineering; breast carcinoma; large cell lymphoma; ctla-4; antigens, cd; tumor cell vaccine; cytotoxic t lymphocyte antigen 4; autoimmune disease; t lymphocyte activation; antigens, differentiation; enterocolitis; costimulation; hypophysitis; t-lymphocyte; ctla 4 antibody; trastizumab
Journal Title: Urologic Oncology: Seminars and Original Investigations
Volume: 24
Issue: 5
ISSN: 1078-1439
Publisher: Elsevier Inc.  
Date Published: 2006-09-01
Start Page: 442
End Page: 447
Language: English
DOI: 10.1016/j.urolonc.2005.08.011
PUBMED: 16962497
PROVIDER: scopus
PMCID: PMC1976273
DOI/URL:
Notes: --- - "Cited By (since 1996): 23" - "Export Date: 4 June 2012" - "CODEN: UOSOA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James P Allison
    130 Allison